New Anglo/U.S. obesity and cardiometabolic specialist Verdiva Bio Ltd. has launched with a massive $411 million series A and a portfolio of GLP-1 and amylin agonists in-licensed from China.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Agios, Astellas, Azafaros, Cour, Denali, Formycon, Johnson, Marengo, Merck, Vigeneron.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Anokion, Bioinvent, Bitterroot, Camp4, Crystal, Eirion, Insilico, Jasper, LB Pharmaceuticals, Sana, Vir.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 1cbio, Acepodia, Alesta, Alloy, Alpha Cognition, Biocytogen, Blackfin Bio, Cassava Sciences, China Medical Systems, Emergent Biosolutions, Esteve, Fauna Bio, Foundery Immune Studio, Galapagos, Helsinn, Ikena, Moma, Novo Nordisk, Oxford Biomedica, Sanofi, Tavros, Valo Health, Vividion, Windtree.
2024 saw the completion of several cellular-resolution brain maps, including the entire fly brain and a comprehensive connections map of a cubic centimeter of human brain. 2025 began with the addition of another important map. In the Jan. 1, 2025, issue of Nature, researchers from the Allen Institute presented a map of areas and cell types where aging most affected the mouse brain.
Wuxi Biologics Co. Ltd. is licensing a preclinical trispecific T-cell engager to Candid Therapeutics Inc. in a deal worth up to $925 million plus royalties.
Yuhan Corp., Oscotec Inc. and Genosco Inc. were three companies with Asian ties to reap benefit from Johnson & Johnson’s stellar top-line Mariposa study results, wherein J&J’s Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) combo regimen beat out Astrazeneca plc’s standard of care in non-small-cell lung cancer (NSCLC).
The wheels of the antibody-drug conjugate (ADC) juggernaut keep on turning, with Araris Biotech AG announcing a deal with a headline value of $780 million to apply its multi-payload linker technology to generate novel ADCs for Chugai Pharmaceutical Co. Ltd.
RSS
